The FDA has approved secukinumab (Cosentyx; Novartis) for the treatment of pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), the company announced. 1 The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results